Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJAOA102 for Menopausal Syndrome
NCT05522621Phase 1Unknown
- Sponsor
- Tongji Hospital
- Start
- Oct 2022
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of TJAOA102 in menopause, sponsored by Tongji Hospital. Primary endpoint: Kupperman Index Score at 6 months. Status: unknown.
02
Drugs
TJAOA102
03
Conditions
menopause
Beyond the preview
Go deeper on NCT05522621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522621.